What type of targeted therapy drug does regorafenib belong to?

Regorafenib (Regorafenib) is a multi-target tyrosine kinase inhibitor (TKI) that is widely used to treat a variety of cancers, especially in patients with advanced tumors who have failed other treatments. It exerts powerful anti-tumor effects by intervening in multiple signaling pathways related to tumor growth, metastasis, angiogenesis, and tumor microenvironment. The mechanism of action of regorafenib makes it an important class of targeted therapeutic drugs that can play a complementary and alternative role in cancer treatment.

The multi-target effect of regorafenib is its key feature. It can inhibit multiple targets including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), KIT, RET, etc. VEGFR Inhibition can reduce the formation of new blood vessels and inhibit tumor blood supply, thereby limiting tumor growth and spread. The inhibition of PDGFR helps to destroy the tumor microenvironment and slow down the migration and invasion of tumor cells.

In addition, the direct effect of regorafenib on tumor cells cannot be ignored. It inhibits molecules such as KIT and RET, which play an important role in the development and progression of many tumors. For example, in gastrointestinal stromal tumors (GIST), KIT mutations are one of the key factors in tumorigenesis, and regorafenib effectively inhibits the progression of this type of tumors by targeting the KIT pathway. Therefore, regorafenib is widely used to treat various tumors such as advanced colorectal cancer, liver cancer, GIST and so on.

The role of regorafenib in the treatment of cancer is manifested in many aspects. It not only works by blocking signaling pathways for tumor growth and metastasis, but also effectively inhibits tumor angiogenesis and changes the tumor microenvironment. Therefore, regorafenib has become an important option in the treatment of advanced cancer, especially in patients who are ineffective or intolerable to traditional treatments. Through its unique multi-target mechanism, regorafenib can provide patients with another anti-tumor treatment option, delay disease progression and improve patient survival.

Reference materials:https://www.stivarga-us.com/